ACR
vs
S
S&P/ASX 300
ACR
Over the past 12 months, ACR has underperformed S&P/ASX 300, delivering a return of -42% compared to the S&P/ASX 300's +11% growth.
Stocks Performance
ACR vs S&P/ASX 300
Performance Gap
ACR vs S&P/ASX 300
Performance By Year
ACR vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Acrux Ltd
Glance View
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a portfolio of generic topical prescription pharmaceutical products which use dermal and transdermal drug delivery technology. The firm's product pipeline includes Evamist, Lenzetto, Jublia, EMLA and Testosterone Topical Solution. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The products offered by the Company are the testosterone topical solution to treat adult males who have low or no testosterone and Estradiol MDTS to treat moderate to severe hot flushes commonly associated with menopause. The company is also developing a range of topical and dermatological generic products for the United States market. The firm operates in the United States, Europe and other markets.
